Matthew Brams - 11 Jun 2024 Form 4 Insider Report for Cingulate Inc. (CING)

Reporting relationship: EVP and Chief Medical Officer
Issuer ticker: CING
Reported as of: 11 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jun 2024, 19:59:46 UTC
Prior SEC filing: 01 Apr 2024
Next SEC filing: 02 Jul 2024
Source filing: View source filing
Reporting owner signature: /s/ Shane J. Schaffer, Attorney-in-Fact

Key filing fact

Matthew Brams filed Form 4 for Cingulate Inc. (CING) on 13 Jun 2024.

Key facts

This page summarizes Matthew Brams's Form 4 filing for Cingulate Inc. (CING).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Jun 2024, 19:59.

Change

Previous filing in this sequence was filed on 01 Apr 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CING transaction Derivative

Stock Option (right to Buy)

Award

Transaction value: $0
Shares: +63,324
Change %
Price: $0.000000
Shares after: 63,324
Date: 11 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 63,324
Exercise price: $1.18
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The stock option grant was approved by Cingulate Inc.'s board of directors on March 4, 2024, subject to stockholder approval of Amendment No.1 to the Cingulate Inc. 2021 Omnibus Equity Incentive Plan (the "Amendment"). Cingulate's stockholders approved the Amendment on June 11, 2024.

Footnote F2

The option vests as follows: 50% on the six-month anniversary of the date of grant and the remaining shares in substantially equal monthly installments over the 30-month period following the initial vesting date.